Factor XI(a) inhibitors for thrombosis: an updated patent review (2016-present)

References

• Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118:1340–1347.
   PubMed Web of Science ®Google Scholar
• Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014;12:1580–1590.
   PubMed Web of Science ®Google Scholar
• Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e24S–43S.
   PubMed Web of Science ®Google Scholar
• Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S–88S.
   PubMed Web of Science ®Google Scholar
• Al-Horani RA, Desai UR. Factor XIa inhibitors: a review of the patent literature. Expert Opin Ther Pat. 2016;26(3):323–345.
   PubMed Web of Science ®Google Scholar
• Al-Horani RA, Afosah DK. Recent advances in the discovery and development of factor XI/XIa inhibitors. Med Res Rev. 2018;38(6):1974–2023.
   PubMed Web of Science ®Google Scholar
• Alamneh EA, Chalmers L, Bereznicki LR. Suboptimal use of oral anticoagulants in atrial fibrillation: has the introduction of direct oral anticoagulants improved prescribing practices? Am J Cardiovasc Drugs. 2016;16:183–200.
   PubMed Web of Science ®Google Scholar
• Barra ME, Fanikos J, Connors JM, et al. Evaluation of dose-reduced direct oral anticoagulant therapy. Am J Med. 2016;129:1198–1204.
   PubMed Web of Science ®Google Scholar
• Hughes S, Szeki I, Nash MJ, et al. Anticoagulation in chronic kidney disease patients-the practical aspects. Clin Kidney J. 2014;7(5):442–449.
   PubMedGoogle Scholar
• Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2017;10:135–143.
   PubMed Web of Science ®Google Scholar
• Black-Maier E, Piccini JP. Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs? Heart. 2017;103(11):807–808.
   PubMed Web of Science ®Google Scholar
• Heine GH, Brandenburg V. Anticoagulation, atrial fibrillation, and chronic kidney disease-whose side are you on? Kidney Int. 2017;91(4):778–780.
   PubMed Web of Science ®Google Scholar
• van Montfoort ML, Meijers JC. Anticoagulation beyond direct thrombin and factor Xa inhibitors: indications for targeting the intrinsic pathway? Thromb Haemost. 2013;110(2):223–232.
   PubMed Web of Science ®Google Scholar
• Nagakura T, Tabata K, Kira K, et al. Selective tissue factor/factor VIIa Inhibitor, ER-410660, and its prodrug, E5539, have anti-venous and anti-arterial thrombotic effects with a low risk of bleeding. Thromb Res. 2013;132(2):271–279.
   PubMed Web of Science ®Google Scholar
• Barbieri CM, Wang X, Wu W, et al. Factor XIIa as a novel target for thrombosis: target engagement requirement and efficacy in a rabbit model of microembolic signals. J Pharmacol Exp Ther. 2017;360(3):466–475.
   PubMed Web of Science ®Google Scholar
• Ankrom W, Wood HB, Xu J, et al. Preclinical and translational evaluation of coagulation factor IXa as a novel therapeutic target. Pharmacol Res Perspect. 2016;4(1):e00207.
   PubMed Web of Science ®Google Scholar
• Al-Horani RA, Abdelfadiel EI, Afosah DK, et al. A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding. J Thromb Haemost. 2019;17(12):2110–2122.
   PubMed Web of Science ®Google Scholar
• Emsley J, McEwan PA, Gailani D. Structure and function of factor XI. Blood. 2010;115:2569–2577.
   PubMed Web of Science ®Google Scholar
• Gailani D, Smith SB. Structural and functional features of factor XI. J Thromb Haemost. 2009;7(Suppl 1):75–78.
   PubMedGoogle Scholar
• Mohammed BM, Matafonov A, Ivanov I, et al. An update on factor XI structure and function. Thromb Res. 2018;161:94–105.
   PubMed Web of Science ®Google Scholar
• Baglia FA, Walsh PN. A binding site for thrombin in the apple 1 domain of factor XI. J Biol Chem. 1996;271:3652–3658.
   PubMedGoogle Scholar
• Renne T, Gailani D, Meijers JC, et al. Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein. J Biol Chem. 2002;277:4892–4899.
   PubMed Web of Science ®Google Scholar
• Sun MF, Zhao M, Gailani D. Identification of amino acids in the factor XI apple 3 domain required for activation of factor IX. J Biol Chem. 1999;274:36373–36378.
   PubMedGoogle Scholar
• Baglia FA, Gailani D, Lopez JA, et al. Identification of a binding site for glycoprotein Ibalpha in the apple 3 domain of factor XI. J Biol Chem. 2004;279:45470–45476.
   PubMed Web of Science ®Google Scholar
• Ho DH, Badellino K, Baglia FA, et al. A binding site for heparin in the apple 3 domain of factor XI. J Biol Chem. 1998;273:16382–16390.
   PubMedGoogle Scholar
• Baglia FA, Jameson BA, Walsh PN. Identification and characterization of a binding site for factor XIIa in the apple 4 domain of coagulation factor XI. J Biol Chem. 1993;268:3838–3844.
   PubMed Web of Science ®Google Scholar
• Yang L, Sun MF, Gailani D, et al. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor. Biochemistry. 2009;48:1517–1524.
   PubMed Web of Science ®Google Scholar
• Wolberg AS, Morris DP, Stafford DW. Factor IX activation by factor XIa proceeds without release of a free intermediate. Biochemistry. 1997;36:4074–4079.
   PubMed Web of Science ®Google Scholar
• Geng Y, Verhamme IM, Messer A, et al. A sequential mechanism for exosite-mediated factor IX activation by factor XIa. J Biol Chem. 2012;287:38200–38209.
   PubMed Web of Science ®Google Scholar
• Matafonov A, Cheng Q, Geng Y, et al. Evidence for factor IX-independent roles for factor XIa in blood coagulation. J Thromb Haemost. 2013;11:2118–2127.
   PubMed Web of Science ®Google Scholar
• Whelihan MF, Orfeo T, Gissel MT, et al. Coagulation procofactor activation by factor XIa. J Thromb Haemost. 2010;8:1532–1539.
   PubMed Web of Science ®Google Scholar
• Choi SH, Smith SA, Morrissey JH. Polyphosphate accelerates factor V activation by factor XIa. Thromb Haemost. 2015;113:599–604.
   PubMed Web of Science ®Google Scholar
• Griffin JH. Role of surface in surface-dependent activation of Hageman factor (blood coagulation factor XII). Proc Natl Acad Sci USA. 1978;75:1998–2002.
   PubMed Web of Science ®Google Scholar
• Scott CF, Silver LD, Purdon AD, et al. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function. J Biol Chem. 1985;260:10856–10863.
   PubMed Web of Science ®Google Scholar
• Gailani D, Broze GJ Jr. Factor XI activation in a revised model of blood coagulation. Science. 1991;253(5022):909–912.
   PubMed Web of Science ®Google Scholar
• Puy C, Tucker EI, Matafonov A, et al. Activated factor XI increases the procoagulant activity of the extrinsic pathway by inactivating tissue factor pathway inhibitor. Blood. 2015;125(9):1488–1496.
   PubMed Web of Science ®Google Scholar
• Puy C, Garland KS, Shirai T, et al. Activated FXI regulates the catalytic activity of ADAMTS13 by removing the CUB domains. RPTH. 2017;1(Suppl. 1):98.
   Google Scholar
• Kossmann S, Lagrange J, Jäckel S, et al. Platelet-localized FXI promotes a vascular coagulation-inflammatory circuit in arterial hypertension. Sci Transl Med. 2017;9:pii: eaah4923.
   PubMed Web of Science ®Google Scholar
• White-Adams TC, Berny MA, Tucker EI, et al. Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2). Arterioscler Thromb Vasc Biol. 2009;29:1602–1607.
   PubMed Web of Science ®Google Scholar
• White-Adams TC, Berny MA, Patel IA, et al. Laminin promotes coagulation and thrombus formation in a factor XII-dependent manner. J Thromb Haemost. 2010;8:1295–1301.
   PubMed Web of Science ®Google Scholar
• James P, Salomon O, Mikovic D, et al. Rare bleeding disorders—bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency. Haemophilia. 2014;20(Suppl 4):71–75.
   PubMed Web of Science ®Google Scholar
• Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost. 2009;7(Suppl 1):84–87.
   PubMed Web of Science ®Google Scholar
• Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia. 2006;12:490–493.
   PubMed Web of Science ®Google Scholar
• Salomon O, Steinberg DM, Zucker M, et al. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost. 2011;105:269–273.
   PubMed Web of Science ®Google Scholar
• Salomon O, Steinberg DM, Koren-Morag N, et al. Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood. 2008;111:4113–4117.
   PubMed Web of Science ®Google Scholar
• Meijers JC, Tekelenburg WL, Bouma BN, et al. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342:696–701.
   PubMed Web of Science ®Google Scholar
• Yang DT, Flanders MM, Kim H, et al. Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events. Am J Clin Pathol. 2006;126:411–415.
   PubMed Web of Science ®Google Scholar
• Suri MF, Yamagishi K, Aleksic N, et al. Novel hemostatic factor levels and risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Cerebrovasc Dis. 2010;29:497–502.
   PubMed Web of Science ®Google Scholar
• Siegerink B, Govers-Riemslag JW, Rosendaal FR, et al. Intrinsic coagulation activation and the risk of arterial thrombosis in young women: results from the Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) case-control study. Circulation. 2010;122:1854–1861.
   PubMed Web of Science ®Google Scholar
• Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood. 2006;108:4045–4051.
   PubMed Web of Science ®Google Scholar
• Berliner JI, Rybicki AC, Kaplan RC, et al. Elevated levels of factor XI are associated with cardiovascular disease in women. Thromb Res. 2002;107:55–60.
   PubMed Web of Science ®Google Scholar
• Büller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015;372(3):232–240.
   PubMed Web of Science ®Google Scholar
• Younis HS, Crosby J, Huh JI, et al. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood. 2012;119(10):2401–2408.
   PubMed Web of Science ®Google Scholar
• Koch AW, Schiering N, Melkko S, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019;133(13):1507–1516.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Chan NC. MAA868 locks factor XIa in a zymogen-like state. Blood. 2019;133(13):1393–1394.
   PubMed Web of Science ®Google Scholar
• Thomas D, Thelen K, Kraff S, et al. BAY1213790, a fully human IgG1 antibody targeting coagulation factor XIa: first evaluation of safety, pharmacodynamics, and pharmacokinetics. Res Pract Thromb Haemost. 2019;3(2):242–253.
   PubMed Web of Science ®Google Scholar
• Lorentz CU, Verbout NG, Wallisch M, et al. Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a Phase 1 first-in-human trial. Arterioscler Thromb Vasc Biol. 2019;39(4):799–809.
   PubMed Web of Science ®Google Scholar
• Hayward NJ, Goldberg DI, Morrel EM, et al. Phase 1a/1b study of EP-7041: a novel, potent, selective, small molecule FXIa inhibitor. Circulation. 2017;136:A13747.
   Web of Science ®Google Scholar
• NCT02608970, NCT03362437, NCT03196206, NCT03000673, NCT02959060, and NCT03341390. [cited 2019 Dec 10]. Available from: https://clinicaltrials.gov
   Google Scholar
• Al-Horani RA, Desai UR. Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides. J Med Chem. 2014;57(11):4805–4818.
   PubMed Web of Science ®Google Scholar
• Afosah DK, Al-Horani RA. Sulfated non-saccharide glycosaminoglycan mimetics as novel drug discovery platform for various pathologies. Curr Med Chem. 2018;25. DOI:10.2174/0929867325666181120101147
   Google Scholar
• Liu W, Edmondson SD, Guo Z, et al.; Merck Sharp & Dohme Corp., US. Pyridine N-oxides as factor XIa inhibitors and their preparation. WO2016015593A1. 2016.
   Google Scholar
• Mertz E, Edmondson SD, Guo Z, et al.; Merck Sharp & Dohme Corp., US. Preparation of 5-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-2-[1-substituted 2-(phenyl)ethyl] pyridine 1-oxide derivatives as factor XIa inhibitors. WO2016018702A1. 2016.
   Google Scholar
• Liu W, Edmondson SD, Guo Z, et al.; Merck Sharp & Dohme Corp., US. Preparation of oxopyridinyl benzimidazole derivatives as factor XIa inhibitors. WO2016018701A1. 2016.
   Google Scholar
• Ogawa AK, Brockunier LL, Tata J, et al.; Merck Sharp & Dohme Corp., US. Pyridine N-oxides as factor XIa and plasma kallikrein inhibitors and their preparation. WO2017095760A1. 2017.
   Google Scholar
• Mertz E, Liu W, Edmondson SD, et al.; Merck Sharp & Dohme Corp., US. Preparation of substituted cyclopenta-pyridine-carboxamides as factor XIa inhibitors. WO2016118403A1. 2016.
   Google Scholar
• Mertz E, Edmondson SD, So S, et al.; Merck Sharp & Dohme Corp., US. Cyclopenta[b]pyridine 1-oxides and 5,6,7,8-tetrahydroquinoline-1-oxides as factor XIa inhibitors and their preparation. WO2016168098A1. 2016.
   Google Scholar
• Shen DM, Kuang R, Kumar P, et al.; Merck Sharp & Dohme Corp., US. Preparation of arylamide pyridine oxides as factor XIa inhibitors for the treatment and prevention of thrombosis and related disease. US20180050022A1. 2018.
   Google Scholar
• Roehrig S, Hillisch A, Strassburger J, et al.; Bayer Pharma, Germany. Preparation of substituted oxopyridine derivatives as factor XIa and plasma kallikrein inhibitors. WO2016046158A1. 2016.
   Google Scholar
• Roehrig S, Jimenez-Nunez E, Schlemmer K-H, et al.; Bayer Pharma, Germany. Preparation of substituted oxopyridine derivatives as factor XIa and plasma kallikrein inhibitors. WO2016046166A1. 2016.
   Google Scholar
• Roehrig S, Hillisch A, Heitmeier S, et al.; Bayer Pharma, Germany. Preparation of factor XIa-inhibiting pyridobenzazepine and pyridobenzazocine derivatives. WO2016046157A1. 2016.
   Google Scholar
• Roehrig S, Jimenez NE, Schlemmer K-H, et al.; Bayer Pharma, Germany. Preparation of substituted oxopyridine derivatives as factor XIa and plasma kallikrein inhibitors. WO2016046164 A1. 2016.
   Google Scholar
• Roehrig S, Hillisch A, Heitmeier S, et al.; Bayer Pharma, Germany. Preparation of substituted oxopyridine derivatives as factor XIa and plasma kallikrein inhibitors. WO2016046159A1. 2016.
   Google Scholar
• Roehrig S, Jimenez NE, Schlemmer K-H, et al.; Bayer Pharma, Germany. Preparation of substituted oxopyridine derivatives as factor XIa and plasma kallikrein inhibitors. WO2016046156A1. 2016.
   Google Scholar
• Roehrig S, Teller H, Heitmeier S, et al.; Bayer Pharma, Germany. Preparation of oxopyridine derivatives as factor XIa inhibitors for the treatment of thrombosis. WO2016146606A1. 2016.
   Google Scholar
• Jimenez NE, Ackerstaff J, Ellerbrock P, et al.; Bayer Pharma, Germany. Preparation of substituted oxopyridine derivatives as factor XIa and plasma kallikrein inhibitors. WO2017037051A1. 2017.
   Google Scholar
• Yang F, Wang W, Li X, et al.; Shanghai Hengrui Pharmaceutical Co., China. Process for preparation of oxopicolinamide derivative and pharmaceutical use. WO2018041122A1. 2018.
   Google Scholar
• Yang F, Qu J, Wang C, et al.; Shanghai Hengrui Pharmaceutical Co., China. Indole-amide derivatives as XIa factor inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cardiovascular diseases. WO2016011940A1. 2016.
   Google Scholar
• Yang F, Wang W, Ying Y, et al.; Shanghai Hengrui Pharmaceutical Co., China. Preparation of oxazoloindole derivatives useful as XIa factor inhibitors for the treatment of cardiovascular disease. CN106496249A. 2017.
   Google Scholar
• Yang F, Chi J, He F, et al.; Shanghai Hengrui Pharmaceutical Co., China. Epoxy-substituted oxopyridine derivative as blood coagulation factor XIa inhibitor and its preparation. CN107793396A. 2018.
   Google Scholar
• Corte JR, Ewing WR, Pinto DJP, et al.; Bristol-Myers Squibb Co., US. Preparation of novel substituted glycine derivatives as factor XIa and/or plasma kallikrein inhibitors. WO2017023992A1. 2017.
   Google Scholar
• Cummings MD, Sekharan S. Structure-based macrocycle design in small-molecule drug discovery and simple metrics to identify opportunities for macrocyclization of small-molecule ligands. J Med Chem. 2019;62(15):6843–6853.
   PubMed Web of Science ®Google Scholar
• Mallinson J, Collins I. Macrocycles in new drug discovery. Future Med Chem. 2012;4(11):1409–1438.
   PubMed Web of Science ®Google Scholar
• Shi J, Ewing WR, Nielsen L, et al.; Bristol-Myers Squibb Co., US. Preparation of diamide macrocycles as factor XIa inhibitors for treatment of thromboembolic disorders. WO2016036893A1. 2016.
   Google Scholar
• Dilger AK, Corte JR, De Lucca I, et al.; Bristol-Myers Squibb Co., US. Pyrimidinones as factor XIa inhibitors and their preparation. WO2016053455A1. 2016.
   Google Scholar
• Smith LM II, Pinto DJP, Corte JR, et al.; Bristol-Myers Squibb Co., US. Preparation of diamide macrocycles as factor XIa inhibitors. WO2016205482A1. 2016.
   Google Scholar
• Pabbisetty KB, Corte JR, Dilger AK, et al.; Bristol-Myers Squibb Co., US. Preparation of factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl p2ʹ moieties. WO2017019819A1. 2016.
   Google Scholar
• Zhu Y, Dilger AK, Ewing WR, et al.; Bristol-Myers Squibb Co., US. Preparation of factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl p2ʹ moieties. WO2017019821A1. 2017.
   Google Scholar
• Shi J, Ewing WR, Pinto DJP; Bristol-Myers Squibb Co., US. Preparation of diamide macrocycles having factor XIa inhibiting activity. WO2017151746A1. 2017.
   Google Scholar
• Corte JR, Dilger AK, Ewing WR, et al.; Bristol-Myers Squibb Co., US. Preparation of macrocycles with novel P1 groups as selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. US20180162821A1. 2018.
   Google Scholar
• Xu J, Ali A, Zhou W, et al.; Merck Sharp & Dohme Corp., US. Macrocyclic compounds as factor XIa inhibitors and their preparation. WO2017074832A1. 2017.
   Google Scholar
• Ali A, Lim Y-H, Xu J, et al.; Merck Sharp & Dohme Corp., US. Preparation of macrocyclic spirocarbamate derivatives as factor XIa inhibitors, pharmaceutically acceptable compositions and their use. WO2017074833A1. 2017.
   Google Scholar
• Zuo Y, Wang J, Lin J, et al.; Sunshine Lake Pharma Co., China. Preparation of macro-heterocyclic compounds as blood coagulation factor XIa inhibitors. WO2018133793A1. 2018.
   Google Scholar
• Zhu J, Song Z, Song L, et al.; Sichuan Kelun-Biotech Biopharmaceutical Co., China. Preparation of macrocyclic amide compounds for preventing or treating thromboembolic diseases. WO2019011166A1. 2019.
   Google Scholar
• Ackerstaff J, Ellermann M, Platzek J, et al.; Bayer Pharma, Germany. Method for producing phenylalanine derivatives as blood-coagulation factor XIa inhibitors. WO2016146599A1. 2016.
   Google Scholar
• Roehn U, Ellermann M, Roehrig S, et al.; Bayer Pharma, Germany. Preparation of substituted phenylalanine derivatives as blood-coagulation factor XIa inhibitors. WO2016146605A1. 2016.
   Google Scholar
• Roehn U, Ellermann M, Roehrig S, et al.; Bayer Pharma, Germany. Preparation of 7-{4-[(2S)-2-({[trans-4-(aminomethyl) cyclohexyl]carbonyl}amino)-3-(phenylamino)-3-oxopropyl]phenyl}-6-methyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid derivatives as factor XIa inhibitors for the treatment of fibrinolytic and thromboembolic diseases. WO2016146604A1. 2016.
   Google Scholar
• Chenard BL, Xu Y, Stassen FL, et al.; Exithera Pharmaceuticals Inc., US. Preparation of substituted azetidinedicarboxamides as factor XIa or kallikrein inhibitors. WO2018118705A1. 2018.
   Google Scholar
• Chenard BL, Xu Y, Stassen FL, et al.; Exithera Pharmaceuticals Inc., US. Preparation of β-lactam derivatives that inhibit Factor XIa or kallikrein (2019) WO2019156929A1. 2019.
   Google Scholar
• Chrusciel RA, Gadwood RC, Hayward NJ, et al.; Exithera Pharmaceuticals Inc., US. Preparation of βLactam derivatives as inhibitors of factor Xia or kallikrein. WO2015120062. 2015.
   Google Scholar
• Yang F, Wang W, Xue T, et al. Preparation of pyrrolidine-amide derivatives as factor XIa inhibitor for treatment of thromboembolism. CN2017-10156222. 2017.
   Google Scholar
• Li S, Xiao SZ, Yipeng S, et al. Anticoagulant small molecule compound and application thereof and medicament containing same. CN109627218A. 2019.
   Google Scholar
• Eder J, Ewert S, Hassiepen U, et al.; Novartis AG, Switzerland. Factor XI antibodies for coagulation therapy. WO2016207858A1. 2016.
   Google Scholar
• Aigner M, Koch AW, Waldhuber M; Novartis AG, Switzerland. Factor XI antibodies for treatment of thrombosis or thromboembolic disease. WO2018116255A1. 2018.
   Google Scholar
• Friedman C, Khder Y, Martin L; Novartis AG, Switzerland. Methods of treatment with anti-factor XI/XIa antibodies. WO2018116267A2. 2018.
   Google Scholar
• Olbrich C, Trill T, Marieke V; Bayer Pharma, Germany. Stable formulations for anti-FXIa antibodies. WO2018134184A1. 2018.
   Google Scholar
• Wilmen A, Buchmueller A, Tucker E; Bayer Pharma, Germany. Preparation of novel chimeric or humanized monoclonal anti-human factor XI and/or XIa antibodies for treatment and prophylaxis of thrombotic or thromboembolic disorders. WO2018054813A1. 2018.
   Google Scholar
• Mikita T, Ely LK, Gao H, et al.; The Regents of The University of California, US. Antibodies to coagulation factor XIa. WO2017015619A1. 2017.
   Google Scholar
• Boross P, Yildiz C, Hack CE; Prothix BV, Netherlands. Monoclonal antibodies against the active site of factor XI. WO2017162791A1. 2017.
   Google Scholar
• Chen Z, Ellsworth K, Milligan J, et al.; Merck Sharp & Dohme Corp., US. Anti-coagulation factor XI antibodies. US20170355780A1. 2017.
   Google Scholar
• Wang W, Yu Q, Liu X; Shanghai Benemae Pharmaceutical CO., China. Anti-coagulation factor XI antibodies for treating and/or preventing coagulation related diseases. WO2018145533A1. 2018.
   Google Scholar
• Wang W, Yu Q, Liu X; Shanghai Benemae Pharmaceutical CO., China. Preparation of anti-coagulation factor XI and/or XIa antibodies for prevention and therapy of thrombosis or sepsis. CN108409863A. 2018.
   Google Scholar
• Chan NC, Weitz JI. AB023, a novel antibody that binds factor XI and blocks its activation by factor XIIa. Arterioscler Thromb Vasc Biol. 2019;39(4):533–535.
   PubMed Web of Science ®Google Scholar
• Tillman BF, Gruber A, McCarty OJT, et al. Plasma contact factors as therapeutic targets. Blood Rev. 2018;32(6):433–448.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Tucker EI, Pine MS, et al. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood. 2010;116(19):3981–3989.
   PubMed Web of Science ®Google Scholar
• David T, Kim YC, Ely LK, et al. Factor XIa-specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis. Sci Transl Med. 2016;8(353):353ra112.
   PubMed Web of Science ®Google Scholar
• Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249:505–510.
   PubMed Web of Science ®Google Scholar
• Rusconi CP, Scardino E, Layzer J, et al. RNA aptamers as reversible antagonists of coagulation factor IXa. Nature. 2002;419:90–94.
   PubMed Web of Science ®Google Scholar
• Woodruff RS, Xu Y, Layzer J, et al. Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer. J Thromb Haemost. 2013;11:1364–1373.
   PubMed Web of Science ®Google Scholar
• Woodruff RS, Sullenger BA. Modulation of the coagulation cascade using aptamers. Arterioscler Thromb Vasc Biol. 2015;35:2083–2091.
   PubMed Web of Science ®Google Scholar
• Soule EE, Bompiani KM, Woodruff RS, et al. Targeting two coagulation cascade proteases with a bivalent aptamer yields a potent and antidote-controllable anticoagulant. Nucleic Acid Ther. 2016;26:1–9.
   PubMed Web of Science ®Google Scholar
• Sullenger BA, Nair S. From the RNA world to the clinic. Science. 2016;352:1417–1420.
   PubMed Web of Science ®Google Scholar
• Sheffield WP, Donkor DA Structure and therapeutic use of human factor xia-specific aptamers. EP3241904A1. 2017.
   Google Scholar
• Donkor DA, Bhakta V, Eltringham-Smith LJ, et al. Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa. Sci Rep. 2017;7(1):2102.
   PubMedGoogle Scholar
• Woodruff RS, Ivanov I, Verhamme IM, et al. Generation and characterization of aptamers targeting factor XIa. Thromb Res. 2017;156:134–141.
   PubMed Web of Science ®Google Scholar
• Ma D, Mizurini DM, Assumpção TC, et al. Desmolaris, a novel factor XIa anticoagulant from the salivary gland of the vampire bat (Desmodus rotundus) inhibits inflammation and thrombosis in vivo. Blood. 2013;122(25):4094–4106.
   PubMed Web of Science ®Google Scholar
• Chen W, Carvalho LP, Chan MY, et al. Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity. J Thromb Haemost. 2015;13(2):248–261.
   PubMed Web of Science ®Google Scholar
• Chen Z, Ding L, Luo X, et al. Application of Sj13 polypeptide in preparing antithrombotic. CN108517009A. 2018.
   Google Scholar
• Gómez-Outes A, García-Fuentes M, Suárez-Gea ML. Discovery methods of coagulation-inhibiting drugs. Expert Opin Drug Discov. 2017;12(12):1195–1205.
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431–441.
   PubMed Web of Science ®Google Scholar
• Heo YA. Andexanet alfa: first global approval. Drugs. 2018;78(10):1049–1055.
   PubMed Web of Science ®Google Scholar
• Moll S, Crona DJ, Martin K. Direct oral anticoagulants in extremely obese patients: OK to use? Res Pract Thromb Haemost. 2018;3(2):152–155.
   PubMed Web of Science ®Google Scholar
• Park CS, Choi EK, Kim HM, et al. Increased risk of major bleeding in underweight patients with atrial fibrillation who were prescribed non-vitamin K antagonist oral anticoagulants. Heart Rhythm. 2017;14(4):501–507.
   PubMed Web of Science ®Google Scholar
• Talamo L, Hillary S, Maitland HS, et al. Safety of doacs in patients of extreme weight. Blood. 2016;128(22):1450.
   Web of Science ®Google Scholar
• Ribic C, Crowther M. Thrombosis and anticoagulation in the setting of renal or liver disease. Hematology Am Soc Hematol Educ Program. 2016;2016(1):188–195.
   PubMedGoogle Scholar
• Ingrasciotta Y, Crisafulli S, Pizzimenti V, et al. Pharmacokinetics of new oral anticoagulants: implications for use in routine care. Expert Opin Drug Metab Toxicol. 2018;14(10):1057–1069.
   PubMed Web of Science ®Google Scholar
• Kouyama S, Ono T, Hagio T, et al. Discovery of ONO-5450598, a highly orally bioavailable small molecule factor XIa inhibitor: the pharmacokinetic and pharmacological profiles. Res Pract Thromb Haemost. 2017;1(Suppl.1):PB2139 [abstract]. 99.
   Google Scholar
• Kouyama S, Ono T, Sakimoto S, et al. Investigation of pharmacodynamic biomarkers and neutralizers for ONO- 7684 (ONO- 5450598), an oral FXIa inhibitor. Res Pract Thromb Haemost. 2019;3(Suppl.1):PB1246 [abstract]. 172.
   Google Scholar